Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Hydrogen Bromide | HCID 260 | — |
| Reactant | HCID 86646613 | HCID 86646613 | — |
| Product | HCID 46937588 | HCID 46937588 | 73.3% |
Reaction Steps
(2R,4S)-Benzyl 2-(2-methyl-2H-tetrazol-5-yl)-4-(3-oxo-2,3-dihydroisoxazol-5-yl)piperidine-1-carboxylate (301 mg, 0.78 mmol) was dissolved in hydrogen bromide (33% in AcOH) (4.1 mL, 23.49 mmol) and reacted for 1 h. The mixture was evaporated and the residue was partitioned between water and EtOAc. The aqueous phase was purified by preparative HPLC on a Kromasil C8 column (10 μm 250×50 ID mm) using a gradient of 0-15% Acetonitrile in H2O/MeCN/NH3 95/5/0.2 buffer over 20 minutes with a flow of 100 mL/min. 5-((2R,4S)-2-(2-Methyl-2H-tetrazol-5-yl)piperidin-4-yl)isoxazol-3(2H)-one (143 mg, 73%) was isolated. 1H NMR (400 MHz, cdcl3) δ 1.70 (qd, 1H), 1.85 (q, 1H), 2.04-2.12 (m, 1H), 2.43-2.50 (m, 1H), 2.91-3.02 (m, 2H), 3.33-3.41 (m, 1H), 4.18 (dd, 1H), 4.32 (s, 3H), 5.68 (s, 1H). HRMS Calcd for [C10H14N6O2+H]+: 251.1256. Found: 251.1233.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US08415378B2 |
|---|
| Source dataset | uspto-grants-2013_04 |
|---|
| ORD ID | ord-88c6eed7443542558c2b89a32bbf3805 |
|---|
| Source note | uspto-grants-2013_04 |
|---|